Sanofi Long Term Debt 2010-2024 | SNY
Sanofi long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
- Sanofi long term debt for the quarter ending September 30, 2024 was $M, a NAN% increase year-over-year.
- Sanofi long term debt for 2023 was $15.528B, a 0.8% decline from 2022.
- Sanofi long term debt for 2022 was $15.653B, a 22.73% decline from 2021.
- Sanofi long term debt for 2021 was $20.258B, a 10.18% decline from 2020.
Sanofi Annual Long Term Debt
(Millions of US $) |
| 2023 |
$15,528 |
| 2022 |
$15,653 |
| 2021 |
$20,258 |
| 2020 |
$22,555 |
| 2019 |
$22,547 |
| 2018 |
$25,990 |
| 2017 |
$16,193 |
| 2016 |
$18,607 |
| 2015 |
$14,566 |
| 2014 |
$17,648 |
| 2013 |
$13,833 |
| 2012 |
$13,786 |
| 2011 |
$17,409 |
| 2010 |
$8,890 |
| 2009 |
$8,313 |
Sanofi Quarterly Long Term Debt
(Millions of US $) |
| 2024-09-30 |
|
| 2024-06-30 |
$13,464 |
| 2024-03-31 |
|
| 2023-12-31 |
$15,528 |
| 2023-09-30 |
|
| 2023-06-30 |
$15,528 |
| 2023-03-31 |
|
| 2022-12-31 |
$15,653 |
| 2022-09-30 |
|
| 2022-06-30 |
$16,965 |
| 2022-03-31 |
|
| 2021-09-30 |
|
| 2021-03-31 |
|
| 2020-09-30 |
|
| 2020-03-31 |
|
| 2019-09-30 |
|
| 2019-03-31 |
|
| 2018-03-31 |
|
| 2017-12-31 |
$16,193 |
| 2017-09-30 |
|
| 2017-06-30 |
$16,708 |
| 2017-03-31 |
|
| 2016-12-31 |
$18,607 |
| 2016-09-30 |
|
| 2016-06-30 |
$16,775 |
| 2016-03-31 |
|
| 2015-09-30 |
|
| 2015-06-30 |
$11,914 |
| 2014-06-30 |
$13,873 |
| 2013-06-30 |
$13,959 |
| 2012-06-30 |
$13,198 |
| 2012-03-31 |
|
| 2011-12-31 |
$17,409 |
| 2011-09-30 |
|
| 2011-06-30 |
$19,122 |
| 2011-03-31 |
|
| 2010-12-31 |
$8,890 |
| 2010-09-30 |
|
| 2010-06-30 |
$9,009 |
| 2010-03-31 |
|
| 2009-12-31 |
$8,313 |
| 2009-09-30 |
|
| 2009-06-30 |
$9,512 |
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$135.190B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
